The Automated DNA Sequencing Facility is a merged Facility which provides investigators with state-of-the-art DNA sequencing and analysis of DNA polymorphisms. The Facility is used by 52 peer-reviewed funded investigators across 10 Research Programs from all three Divisions. Ninety-nine and one-half percent (99.5%) of the users have peer-reviewed funding. Richard Hardy, Ph.D. (Program Leader, Immunobiology) assumed direction of the Facility in 1993. Automated sequencing using an ABI Model 373 was set up in 1994. Model 377 sequencers were subsequently added, one in 1995, and another in 1997. A third 377 replaced the original 373 in 2002. Recently, two of the 377s have been replaced by a modern ABI 3100 capillary instrument, providing more reliable high-throughput sequencing. The Sequencing Facility provides Fox Chase Cancer Center (FCCC) investigators with computer-readable sequences of their DNA samples in a timely and cost effective manner, generating data more rapidly and of greater read-length compared to manual sequencing. Automated sequence analysis is used by investigators to verify DNA constructs, to identify mutations, and to determine the structure of newly cloned genes. Sequencing large genes (5-20 Kb) is much more tractable using automated sequence analysis, generating results in a few weeks, as compared to months using manual sequencing. The volume of usage of the Facility has continued to increase steadily over the past five years from 17,000 sequences in 1998 to over 28,000 in 2003 (64% increase). In addition to sequencing, analysis of DNA polymorphisms, important in genetic mapping studies, is also available in the Facility using """"""""GeneScan"""""""" software on the 377. Equitable access to the Facility is assured by a Faculty Oversight Committee. The Facility was rated """"""""Outstanding"""""""" at the last CCSG review.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-44
Application #
7310498
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
44
Fiscal Year
2006
Total Cost
$104,391
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Diefenbach, Michael A; Benedict, Catherine; Miller, Suzanne M et al. (2018) Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT. Transl Behav Med 8:876-886
Ross, Kayleigh C; Chin, Kevin F; Kim, Daehwan et al. (2018) Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 9:13324-13336
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Mazor, Anna M; Mateo, Alina M; Demora, Lyudmila et al. (2018) Breast conservation versus mastectomy in patients with T3 breast cancers (>?5 cm): an analysis of 37,268 patients from the National Cancer Database. Breast Cancer Res Treat :
Ingram, Justin P; Tursi, Sarah; Zhang, Ting et al. (2018) A Nonpyroptotic IFN-?-Triggered Cell Death Mechanism in Nonphagocytic Cells Promotes Salmonella Clearance In Vivo. J Immunol 200:3626-3634
Chang, Wen-Chi L; Jackson, Christina; Riel, Stacy et al. (2018) Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 67:1290-1298
Mishra, Om P; Popov, Anatoliy V; Pietrofesa, Ralph A et al. (2018) Synthetic secoisolariciresinol diglucoside (LGM2605) inhibits myeloperoxidase activity in inflammatory cells. Biochim Biophys Acta Gen Subj 1862:1364-1375
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121

Showing the most recent 10 out of 1280 publications